Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3127760 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy males or females as determined by medical history and physical examination~* Male participants agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product~* Female participants not of child-bearing potential~* Have a body mass index of 18.5 to 32 kilograms per square meter (kg/m\^2) inclusive~* Are normotensive (defined as supine systolic blood pressure \[BP\] less than 140 millimeters of mercury \[mm Hg\] and diastolic BP less than 90 mm Hg) without use of any antihypertensives~Exclusion Criteria:~* Have known allergies to LY3127760, related compounds or any components of the formulation, celecoxib or sulfonamides, or history of significant atopy. Participants with known aspirin allergy or allergic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) should also be excluded~* Have any current or prior history of a significant gastrointestinal illness such as peptic ulcer disease, gastrointestinal (GI) bleeding, chronic gastritis, inflammatory bowel disease or chronic diarrhea~* Have evidence of other chronic liver disease, including but not limited to chronic alcoholic disease, nonalcoholic steatohepatitis, recent history (within 3 months of screening) of acute viral hepatitis or chronic autoimmune hepatitis~* Have used any NSAIDs, celecoxib, aspirin or acetaminophen (at doses greater than 1 gram per day), anticoagulants or antiplatelet agents within 14 days of admission~Part 2 and Part 3 only~* Have 1 plus pretrial pitting edema or 2 plus ankle or pedal edema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY3127760 (Single) (Type: EXPERIMENTAL): Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
- Placebo (Single) (Type: PLACEBO_COMPARATOR): Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
- LY3127760 (Multiple) (Type: EXPERIMENTAL): Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
- Placebo (Multiple) (Type: PLACEBO_COMPARATOR): Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
- Celecoxib (Multiple) (Type: ACTIVE_COMPARATOR): Multiple oral doses of 400 mg celecoxib administered QD for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).